Drug Trial Radar · NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
594
Planned (sponsor's estimate)
Start
May 2, 2025
Primary completion
Sep 2028
Study completion May 2032
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- DualityBio Inc.
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Conditions
- Advanced Lung Cancer
Interventions
BNT324Biological
Intravenous infusion
BNT327Biological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose levelTime frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days]
- Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose levelTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
- Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose levelTime frame: From the time of the first dose of IMP to 90 days after the last dose of IMP or until new anticancer therapy is started, whichever occurs first
- Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment armTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
- Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment armTime frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
- Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment armTime frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months
- Part 2 cohorts 3-7 - ORR by cohortTime frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months
Locations
91 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona · Recruiting
Precision NextGen Oncology and Research Center
Beverly Hills, California · Recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
UCLA - David Geffen School of Medicine
Santa Monica, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
University of Iowa Hospitals & Clinics PARENT
Iowa City, Iowa · Recruiting
Mayo Clinic-Rochester
Rochester, Minnesota · Recruiting
Regional Cancer Care Associates
Belleville, New Jersey · Recruiting
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai PRIME
New York, New York · Recruiting
Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
Cleveland, Ohio · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Oncology - Northeast
Tyler, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
Bendigo Hospital
Bendigo, Victoria, Australia · Recruiting
Barwon Health
Geelong, Victoria, Australia · Recruiting
Sunshine Hospital
Saint Albans, Victoria, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
The First Affiliated Hospital of Xiamen University
Fujian, China · Recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guandong, China · Recruiting
Xuzhou Central Hospital
Xuzhou, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi Zhuang, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Weihui, Henan, China · Recruiting
Henan Provincial Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Jingzhou First People's Hospital
Jingzhou, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Yichang Central People's Hospital
Yichang, Hubei, China · Recruiting
Hunan Province People's Hospital
Changsha, Hunan, China · Recruiting
Nanjing Chest Hospital
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.